Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab Monotherapy and Combination with Nivolumab in Advanced Solid Tumors
NCT02966548Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of relatlimab in solid tumor (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of adverse events (AE) at 2.2 years, Number of serious adverse events (SAE) at 2.2 years and 2 more. Started Jan 2017; status: completed.
02
Drugs
relatlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02966548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966548.